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Abstract 
Background:  The prevalence and consequences of hypervolemia in kidney transplant 
recipients (KTRs) have not been investigated.  Specifically, its impact on blood pressure (BP) 
and relationship with N-terminal fragment of prohormone B-type natriuretic peptide (NT-
proBNP) are unknown.  The objectives of this study were to establish the prevalence of 
hypervolemia among clinically stable KTRs, investigate the predictors of post-transplant 
hypervolemia, assess its impact on blood pressure, and determine its relationship with NT-
proBNP. 
Methods:  This single-centre cross-sectional study enrolled 123 clinically stable KTRs.  
Extracellular volume status was determined by multi-frequency bioimpedance analysis.  Mild 
and severe hypervolemia were defined as percentage volume expansion of >7% and >15% 
respectively.  Systolic BP (SBP) and diastolic BP (DBP) were measured, with mean arterial 
pressure (MAP) calculated.  Serum NT-proBNP was quantified using a non-competitive 
immunoluminometric assay.  Potential demographic, nutritional and clinical predictors of 
extracellular volume status, BP and NT-proBNP levels were assessed. 
Results:  Hypervolemia was present in 30% of KTRs, with 5% classified as severe 
hypervolemia.  Significant predictors of volume expansion were increased sodium intake, 
advancing age, and reduced fat mass (p<0.01 for all associations).  Hypervolemia was the only 
independent predictor of elevated MAP, SBP and DBP (p<0.001 for all associations).  Raised 
NT-proBNP levels were independently associated with both hypervolemia (p=0.01) and 
allograft dysfunction (p=0.03). 
Conclusions:  Hypervolemia is unexpectedly common among clinically stable KTRs. It is 
closely associated with elevated BP.  The relationship with increased sodium intake signals 
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potential therapeutic focus.  Further study is warranted to prospectively investigate objective 
measures of extracellular volume status among KTRs. 
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Introduction 
 
Hypervolemia (or volume expansion) represents isotonic expansion of the extracellular fluid 
compartment caused by abnormal retention of water and sodium, manifesting as fluid 
accumulation and swelling in the extremities or lung tissues.  It is common among patients with 
end-stage renal disease (ESRD) requiring maintenance dialysis1-4, and is associated with 
increased morbidity and mortality1-3,5.  For many of these patients, kidney transplantation is a 
preferred option of renal replacement therapy to correct metabolic abnormalities.  It is assumed 
that hypervolemia no longer represents a major problem following transplantation, but no study 
to date confirms or refutes this.     
 
In addition, hypervolemia is associated with hypertension in patients on haemodialysis2 and 
peritoneal dialysis3, but this relationship has not been studied in kidney transplant recipients 
(KTRs) despite this complication arising in 75-90% of these patients6.   
 
B-type Natriuretic Peptide (BNP) is a cardiac hormone that is synthesized as an amino acid 
precursor protein and undergoes intracellular modification to a Prohormone BNP (pro-BNP)7.  
It is secreted predominately from the ventricles in response to increased stretch of the 
ventricular wall7.  Upon release into the circulation, pro-BNP is cleaved into the biologically 
active 32-amino acid C-terminal fragment BNP, and the biologically inactive 76-amino acid N-
terminal fragment (NT-proBNP)7.  NT-proBNP possesses a longer half-life time than the 
biologically active counterpart, hence delivering a superior reflection of pathophysiological 
situation leading to raised BNP levels8.  Due to renal metabolism of NT-proBNP, 
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concentrations also rise with the progression of chronic kidney disease (CKD)9.  Recent studies 
have confirmed that it is a marker of extracellular volume overload rather than cardiac 
dysfunction per se in maintenance dialysis patients10-13.  However, little research has examined 
this relationship following transplantation, with the 2 studies conducted to date highlighting the 
inverse relationship between NT-proBNP and allograft function14,15. 
 
The primary objectives of this study were to determine the prevalence and predictors for 
hypervolemia in a stable kidney transplant cohort, and to assess its association with post-
transplant hypertension.  Secondly, we sought to explore the utility of serum NT-proBNP as a 
correlate of hypervolemia and renal dysfunction in this cohort.  
 
Results 
 
Population characteristics 
 
The characteristics of the studied population are shown in Table 1. The mean percentage 
volume expansion (%VE) ± standard deviation (SD) for the cohort was 2.6±7.7%, ranging from 
-17.0% to +25.0%.  Based on denoted criteria (described in Materials and Methods), the 
prevalence of hypovolemia in KTRs was 11% (13 patients), normovolemia was 59% (73 
patients), mild hypervolemia was 25% (31 patients displaying %VE between 7.1 and 15.0%), 
and 5% suffered from severe hypervolemia (6 patients displaying %VE >15.0%).   
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Factors predicting extracellular volume status 
 
On univariate analysis, increasing values for %VE were associated with the following:  higher 
sodium intake (relationship is shown in Figure 1), higher fluid intake, older age, pre-existing 
diabetes, male gender, the use of either an angiotensin-converting-enzyme-inhibitor (ACEI) or 
angiotensin-receptor blocker (ARB) (grouped as a single category), and the number of 
antihypertensive medications.  The effect sizes for the univariate analyses are shown in SDC, 
Table 1.  In the multivariate analysis, only increased sodium intake (beta coefficient, β = 1.7; 
95% confidence interval, CI = 1.2, 2.4; p<0.001) and advancing age (β = 1.8; 95% CI = 1.0, 
2.6; p<0.001) retained statistical significance.  In addition, an association emerged in the 
multivariate analysis between increased %VE and reduced fat tissue index (FTI) (β = -1.4; 95% 
CI = -2.2, -0.5; p=0.002).  A 51% of the variation in extracellular volume status (%VE) was 
explained by these variables (R2: 51%; SDC, Table 1). 
 
Extracellular volume status and blood pressure 
 
Increasing volume status (higher %VE) was associated with progressive increases in all 
measures of blood pressure (BP) (systolic blood pressure, SBP, r=0.83, p <0.001; diastolic 
blood pressure, DBP, r=0.60, p<0.001; mean arterial pressure, MAP, r=0.78, p<0.001; Figure 
2a).  A significant difference across categories of volume status (“hypovolemia”; 
“normovolemia”; “mild hypervolemia”; “severe hypervolemia”) was seen, with increased BP at 
higher degrees of extracellular volume status (Figure 2b).   
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The univariate and adjusted analyses describing the predictors of MAP, SBP and DBP are 
shown in SDC, Table 2; SDC, Table 3; and SDC, Table 4 respectively.  The following 
predictor variables displayed univariate, unadjusted associations with higher values for all 
measures of BP (MAP, SBP and DBP):  increasing %VE, increased sodium intake 
(associations shown in Figure 3), older age, diabetes (either pre-existing diabetes, pre-DM; or 
new onset diabetes after transplantation, NODAT), the use of either an ACEI or ARB, 
hypoalbuminaemia, male gender, and number of antihypertensive medications.  In addition, 
higher fluid intake was associated with higher MAP and SBP readings, but not DBP.  However, 
in the adjusted model, the only independent predictor of BP was a higher %VE, with this effect 
seen for MAP (β = 6.6; 95% CI = 5.6, 7.6; p<0.001), SBP (β = 9.8; 95% CI = 8.5, 11.0; 
p<0.001), and DBP (β = 4.9; 95% CI = 3.7, 6.2; p<0.001).  Of note, a substantial proportion of 
BP variation could be explained by this single predictor variable (62%, 69% and 35% for MAP, 
SBP and DBP as shown in SDC, Table 2; SDC, Table 3; and SDC, Table 4 respectively). 
 
NT-proBNP as a marker of hydration status and allograft function 
 
Median serum NT-proBNP level in this cohort of KTRs was 291.0 (interquartile range, IQR: 
65.0-700.4) pmol/L.  NT-proBNP levels demonstrated a positively skewed distribution and 
underwent logarithmic transformation prior to parametric analysis.  On univariate analysis, 
higher %VE, lower estimated glomerular filtration rate (eGFR), and reduced haemoglobin (Hb) 
level were associated with higher values for NT-proBNP (SDC, Table 5).  In the multivariate 
analysis, increasing %VE (Ratio, R = 1.16; 95% CI = 1.03, 1.29; p=0.01), decreasing eGFR (R 
= 0.95; 95% CI = 0.90, 0.99; p=0.03), and lower Hb level (R = 0.74; 95% CI = 0.58, 0.96; 
p=0.02) retained significant associations with NT-proBNP.  In addition, the absence of a 
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dihydropyridine calcium channel blocker (CCB) prescription (R = 0.63; 95% CI = 0.45, 0.89; 
p<0.01) and either current or previous smoking history (R = 1.46; 95% CI = 1.04, 2.05; p=0.03) 
were significant predictors of raised NT-proBNP levels in the multivariate model.  The 
relationships of NT-proBNP with %VE and renal allograft function are demonstrated in Figure 
4a and Figure 4b respectively.  A 21% of the variation in NT-proBNP was explained by the 
variables in the final multivariate model. 
 
Discussion 
 
This is the first study to address in detail the prevalence, predictors, and consequences of 
hypervolemia in KTRs.  Based on the previously established definition of hypervolemia, 30% 
of KTRs were hypervolemic, of whom 5% suffered from severe hypervolemia.  Despite a lower 
incidence when compared to continuous ambulatory peritoneal dialysis3 or haemodialysis16 
populations, this degree of hypervolemia was unexpected, and is noteworthy in light of the 
specific selection of a clinically and biochemically stable kidney transplant cohort for this 
study.  Hypervolemia was associated with increasing sodium intake, highlighting an important 
target for intervention.  Dietary sodium restriction has not been formally examined in KTRs, 
but has gained attention in other contexts17.  The daily sodium intake in the current cohort of 
KTRs was 2725mg (118mmol), lower than previously reported (3588 mg/156mmol per day)18, 
but well above the recommendation of Dietary Approach to Stop Hypertension (DASH) 
guideline (1500-2300 mg/65-100 mmol per day)19.  Collectively, these findings suggest that 
reducing sodium intake in line with the DASH diet should be recommended for KTRs 
presented with hypervolemia. 
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A recent study demonstrated a relationship between increased sodium intake and higher BP, 
although the contribution of extracellular volume status was not evaluated therein18.  Whilst the 
results of the current study confirmed a univariate association between sodium intake and BP, 
this relationship did not hold when the effect of extracellular volume status was taken into 
account.  Indeed, hypervolemia was identified as the only independent risk factor for elevated 
BP, which has a recognised impact upon long-term patient and graft outcomes20-22.  Although 
this relationship between hypervolemia and elevated BP resonates with findings in dialysis 
patients2,3,23, this has not been previously demonstrated in KTRs.   
 
Pertinently, the American Society of Hypertension24 acknowledges the possible role of volume 
expansion and potential therapeutic role of diuretics in post-transplant hypertension.  Other 
expert review articles also recognise volume expansion as a potential risk factor, although 
remain guarded over the use of diuretic therapies25,26.  In the current study, the prevalence of 
diuretic usage was only 15%, with furosemide being the only diuretic prescription. No 
association between furosemide usage and volume status was observed, but this may be a 
reflection of “confounding by indication”.  Furthermore, the median dosage of furosemide in 
this study cohort was 40mg, a dosage which may be insufficient to target hypervolemia in 
KTRs with a mean eGFR of 44mL/min27.  Such confounding may also be responsible for the 
association between renin-angiotensin system blockers (ACEI and ARB), and volume overload, 
MAP, SBP and DBP, although these associations did not persist in the adjusted analysis.  
 
In regard to other determinants of extracellular volume status, an inverse association between 
fat mass and volume status was observed in the current study.   This phenomenon has been 
demonstrated in a non-transplanted population28, which now extends to the kidney transplant 
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population.  Interestingly renal dysfunction was not identified as one of the predictors of 
volume status and blood pressure in this study.  However, based on the statistical point 
estimates, eGFR displayed inverse associations with volume overload, MAP, SBP and DBP, 
and the absence of statistical significance may reflect the study size and range of renal function 
encountered in this study, and certainly the current results do not exclude the importance of 
renal function in this setting.  
  
Based on the findings from this study, a multi-modality approach involving the DASH diet and 
increased diuretic usage may be beneficial in the treatment of volume overload and 
hypertension in KTRs.  Previous studies have shown that synergistic hypotensive effects were 
achieved when sodium restriction and diuretics were used in combination29,30.  In particular, the 
DASH diet, comprising high fruits, vegetables, whole-grains, and low-fat dairy products; and 
low fat, refined carbohydrates and sodium, has been shown to substantially lower blood 
pressure in large, randomised, controlled trials19,31,32.  It has also been proven to potentiate the 
benefits of antihypertensive medication treatment31.  Diuretic therapy should be titrated in 
accordance with volume status and blood pressure.  Crucially, meticulous monitoring of both 
volume status and blood pressure should be in place to ensure optimal management of 
hypertension in KTRs.  In particular, increasing fluid intake is often promoted particularly in 
the early period post-transplantation, yet also displayed univariate association with volume 
overload, MAP and SBP, thereby highlighting the importance of judicious assessment of 
extracellular volume in these patients.  Indeed, the findings from this study suggest that more 
widespread and accurate evaluation of extracellular volume status may facilitate the clinical 
management of KTRs, and sets the scene for interventional measures which have shown benefit 
in a recent haemodialysis-based trial33.  It is hoped that the findings of this study will highlight 
the importance of extracellular volume status assessment in the management of hypertension, a 
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tool yet to be incorporated into international guidelines from Kidney Disease: Improving 
Global Outcomes (KDIGO)34, European Renal Best Practice (ERBP) Work Group35 and United 
Kingdom Renal Association (UKRA)36. 
 
The independent association between an objective measure of hypervolemia and raised NT-
proBNP level is a novel and noteworthy finding of this study, confirming and extending 
findings from the non-transplanted populations, predominantly patients undergoing dialysis10-
13.  Additionally, reduced allograft function was independently associated with raised NT-
proBNP levels, in keeping with findings from previous studies among KTRs14,15, due to a 
reduced renal clearance of NT-proBNP.  Although previous studies have suggested NT-
proBNP as a marker of cardiac dysfunction in dialysis patients37,38, interpretation of these 
studies is limited by a lack of concomitant and objective measurement of volume status, and by 
the variation in NT-proBNP levels depending on the timing of blood sampling relative to 
dialysis treatment.  In fact, the most detailed study in dialysis which employed standardised 
sampling times, simultaneous echocardiography and bioimpedance-based extracellular fluid 
volume measurements, showed that NT-proBNP was dependent on volume overload per se, 
rather than the echocardiographic parameters of cardiac dysfunction10,11.  The single study in 
KTRs addressing the relationship between echocardiography and NT-proBNP level likewise 
found no relationship between the two parameters14.  Whilst cardiac function was not assessed 
in the current study, the findings from this study certainly support the concept that NT-proBNP 
levels reflect volume status.  However, an important caveat is the high variability in the 
relationship between NT-proBNP levels and both %VE and eGFR.  This suggests that although 
NT-proBNP may be a marker of volume expansion and renal dysfunction, it cannot yet be 
considered as an accurate surrogate for either.  The utility of serial NT-proBNP measurements 
cannot be discerned by the current study. 
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Other factors independently associated with elevated NT-proBNP levels included smoking 
(current and/or ex- smoker), reduced level of Hb, and the absence of CCB prescription as an 
antihypertensive agent.  Although the mechanisms behind these findings are not fully 
understood and were not the focus of the present study, these results are in keeping with 
previous observations in non-transplant cohorts39-45, and reflecting the “face validity” of the 
current findings.  
 
This study has limitations that should be acknowledged.  It represents a single-centre 
experience, and validations of the findings are needed in other cohorts.  Also, transplant renal 
artery stenosis is a potential cause for post-transplant hypertension and volume expansion.  
However, it was not systematically sought in this study due to an estimated prevalence of only 
5-10%46, and the lack of detection is unlikely to have confounded the results.  The cross-
sectional nature of this study is unable to establish the causal relationship between predictor 
and outcome variables.  Long-term longitudinal follow-up and experimental interventions are 
now required to robustly evaluate the impact of extracellular volume status on relevant end-
points in kidney transplantation. 
 
In summary, this is the first study to investigate the prevalence, predictors, consequences, and 
biochemical markers of hypervolemia in KTRs.  It points at potential targets for intervention, 
thereby expanding future avenues for basic and clinical research.  
 
Materials and Methods 
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Participants and study design 
 
KTRs beyond 1 year post-transplantation, with stable graft function (<10% increase in serum 
creatinine over preceding 6 months), were recruited to this cross-sectional study between April 
2010 and April 2013.  Exclusion criteria included episodes of acute rejection within the last 6 
months, evidence of sepsis in the last 6 weeks, known active malignancy or chronic infection, 
history of thyroid disease or adrenal insufficiency, and contra-indications for use of bio-
impedance based body composition assessment (implanted or external electronic devices, 
metallic implants, amputations, pregnancy, and lactation).  Of 133 patients approached, 10 did 
not participate (mainly due to work commitment).  The study was approved by the local 
research ethics committee, and was conducted in accordance with the principles of the 
Declaration of Helsinki. 
 
Data Collection 
 
Demographics and clinical parameters 
 
Age, gender, ethnicity, and time post-transplantation were collected from patients’ medical 
records.  Smoking status (never smoked, current and ex- smoker) was collected by 
questionnaire.  The following clinical parameters were retrieved from patients’ medical 
records:  1) presence of diabetes, either pre-transplantation (pre-DM) or new onset diabetes 
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after transplantation (NODAT), 2) prior acute rejection episodes, 3) immunosuppressive 
medication usage, either prednisolone, calcineurin inhibitor or adjunctive antiproliferative 
agent, 4) use of anti-hypertensive medications, either angiotensin-converting-enzyme inhibitor 
(ACEI), angiotensin-receptor blocker (ARB), beta-adrenergic blocker (BAB), dihydropyridine 
calcium-channel blocker (CCB), or alpha-adrenergic blocker (AAB), and 5) use of diuretic. 
 
Systolic BP (SBP) and diastolic BP (DBP) were measured semi-recumbent with a fully-
automatic upper-arm digital blood-pressure monitor (Spot Vital Signs ® LXi, Welch Allyn). 
Six readings over an 8-10 minute period were taken, with the first reading ignored, and the 
mean of the remaining 5 used for analysis.  This protocol for BP monitoring has been shown to 
produce measurements comparable to that derived from the 24-hour ambulatory blood pressure 
monitor, the “gold standard” for the diagnosis of hypertension47.  Mean arterial pressure (MAP) 
was subsequently calculated using the formula (2DBP + SBP)/318. 
 
Laboratory parameters 
 
Blood samples were collected for measurement of high-sensitivity C-reactive protein (hsCRP), 
albumin (Alb), haemoglobin (Hb) and estimated glomerular filtration rate (eGFR) derived 
using 4-variable modification of diet in renal disease equation48.  Morning urine was collected 
for assessment of albumin : creatinine ratio (ACR).  Analyses were undertaken in accredited 
hospital haematology and biochemistry laboratories.   
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Serum NT-proBNP was measured using a non-competitive immunoluminometric assay as 
described by Khan and colleagues49.  This highly specific assay shows no cross-activity with 
atrial natriuretic peptide, BNP, or C-type natriuretic peptide49.  The inter- and intra- assay 
coefficients of variation were 2.3 and 4.8% respectively49. 
 
Sodium and fluid intakes 
 
Sodium and fluid intakes were estimated by a 3-day food diary.  A multiple-day food diary 
provides a good estimate of individual’s sodium intake50, comparable to that derived from the 
mean 24-hour urinary sodium excretion50,51, and produces a reliable and valid record of fluid 
intake in free-living humans52.  Participants were given detailed written instructions on 
completing an accurate dietary record for a 3-day period, which included one weekend day, 
within one week prior to attending the research visit.  These instructions were accompanied by 
verbal explanation from the researcher, which included training in portion size estimation and 
documentation for both dining in and eating out.  The dietary records were reviewed by the 
researcher for accuracy and completeness at the research visit.  Data was entered into Dietplan6 
P3 (Forestfield Software Ltd) nutrition analysis program by the same researcher, avoiding 
inter-observer variation.  Total daily intakes of fluid, energy, all macro- and micro- nutrients, 
were calculated by this program.  No patients were prescribed sodium-containing oral 
medication at the time of the study. 
 
Measurement of body composition and hydration status; definition of fluid overload 
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Body composition and extracellular volume status were assessed by whole body bio-impedance 
spectroscopy (“body composition monitor” [BCM]; Fresenius Medical Care, Germany).  This 
device has been used in dialysis patients extensively5, and has been validated against reference 
methods for volume status and body composition53.  The BCM utilises an algorithm based on a 
3-compartment body model to evaluate extracellular and intracellular fluid volumes28.  
Absolute extracellular volume expansion was determined by calculating the difference between 
the actual amount of extracellular fluid in the body detected by the BCM and the expected 
amount of extracellular fluid (ECF) predicted by the BCM under normal physiological (i.e. 
normovolemia) conditions5,54.  Percentage volume expansion (%VE) is therefore defined as: 
[(Absolute extracellular volume expansion × 100) / Expected ECF volume].  In a normal 
reference population, the 90th and the 10th percentiles of %VE is ±7%5,55.  Increased mortality 
in haemodialysis patients is observed when %VE >15%56,57.  Hence, established definitions 
(and those used in the current study) are based on %VE, <-7.0% representing “hypovolemia”, 
within ±7.0% indicating “normovolemia”, between 7.1% and 15.0% denoting “mild 
hypervolemia”, and >15.0% demonstrating “severe hypervolemia”. 
 
Measurements were carried out in a standard manner while the patient was lying supine in a flat 
and non-conductive bed.  The inbuilt physiological body composition model measures whole-
body bioimpedance spectroscopy at 50 frequencies (5 to 1000 kHz) via electrodes placed on the 
wrist (proximal to the transverse) and the ankle (arch on the superior side of the foot) on the 
same side of the body.  Results for %VE, together with Lean Tissue Index (LTI [kg/m2]) and 
Fat Tissue Index (FTI [kg/m2]), were displayed after each measurement.   
 
Statistical analysis 
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Statistical analyses were performed using STATA.  Results were presented as mean ± standard 
deviation (SD) for normally distributed data or median (interquartile range, IQR) for non-
normally distributed data.  Unadjusted univariate relationships were evaluated with Pearson’s 
correlation coefficients, and one-way analysis of variance (ANOVA) followed by Tukey’s 
post-hoc test for multiple-group comparisons.  
 
Linear regression analysis was used to determine the associations between predictor variables 
and the continuously-distributed outcome variables, with logarithmic transformation of non-
normally distributed data prior to analysis.  The analyses were performed in two stages.  
Initially, the effect of each variable was examined in a series of univariate regression analyses.  
Subsequently, the joint effect of variables demonstrating some evidence of association on 
univariate analysis (p<0.20) was examined in a multivariable regression analysis, using a 
backwards selection procedure to derive the final model.  A type 1 error rate ≤5% (p≤0.05) was 
considered significant in the final model.   
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Table 1.  Population Characteristics 
 Characteristics 
 
Sample size n = 123 
Gender (%) Male = 56 Female = 44 
*Ethnicity (%) 
 
Caucasian = 77                
Afro-Caribbean = 5 
Asian = 16                     
Others = 2 
†Mean age (years) 50 ± 15 
‡Median time post-transplantation (years) 5 (2-11) 
§Smoking status (%) 
 
Non-smoker = 63 
Ex-smoker = 29 
Current smoker = 8 
†Mean extracellular volume status: %VE (%) 2.6 ± 7.7 
‡Median level of NT-proBNP (pmol/L) 291.0 (65.0-700.4) 
Blood pressure 
†Mean systolic blood pressure (mmHg) 
†Mean diastolic blood pressure (mmHg) 
†Mean arterial pressure (mmHg) 
 
141 ± 19 
82 ± 13 
101 ± 13 
Immunosuppressive medication usage 
Calcineurin inhibitor (%) 
Adjunctive antiproliferative agent (%) 
Prednisolone (%) 
 
79 
87 
77 
Dosage of immunosuppressive medications 
‡Median dose of Tacrolimus (mg/day) 
‡Median dose of Cyclosporin (mg/day) 
†Mean dose of Mycophenolate Mofetil (mg/day) 
†Mean dose of Azathioprine (mg/day) 
‡Median dose of Prednisolone (mg/day) 
 
4.0 (2.5-6.0) 
150 (150-200) 
987 ± 392 
77 ± 36 
5 (5-5) 
Anti-hypertensive medication usage 
ACEI / ARB (%) 
BAB (%) 
CCB (%) 
AAB (%) 
 
43 
21 
48 
39 
Diuretic medication usage 
Furosemide, exclusively (%) 
 
15 
‡Median dosage of Furosemide (mg) 40 (30-40) 
Presence of diabetes (%) 
 
Non-diabetic = 75 
Pre-DM = 10 
NODAT = 15 
Previous episodes of acute rejection (%) Yes = 23 No = 77 
‡Median hsCRP (mg/L) 2.4 (1.0-4.9) 
†Mean Hb (g/dL) 12.6 ± 1.6 
†Mean Alb (g/L) 44.5 ± 3.2 
†Mean eGFR (mL/min) 44.2 ± 17.3 
‡Median ACR (mg/mmol) 4.4 (1.6-14.7) 
‡Median sodium intake (mg) 2725 (2131-3248) 
‡Median fluid intake (mL) 2567 (2100-3672) 
Body Composition 
Body mass index, BMI (kg/m2) 
Lean Tissue Index, LTI (kg/m2) 
Fat Tissue Index, FTI (kg/m2) 
 
27.4 ± 5.8 
13.9 ± 3.0 
13.3 ± 6.3 
*For the purpose of statistical analysis, the ethnicity of patients classified as “Afro-Caribbean”, “Asian” and “Others” was grouped as “Non-Caucasian”, 77% “Caucasian” versus 23% “Non-
Caucasian”.   
†Normally distributed data, results expressed as mean ± standard deviation (SD). 
‡Non-normally distributed data, results expressed as median (interquartile range, IQR).   
§For the purpose of statistical analysis, smoking status was arranged into 2 categories, “non-smoker” versus “current smoker and ex-smoker”, 63% and 37% of patients respectively. 
Abbreviations:  %VE=Percentage Volume Expansion; NT-proBNP=N-Terminal pro B-type Natriuretic Peptide; ACEI=Angiotensin-Converting-Enzyme Inhibitor; ARB=Angiotensin-
Receptor Blocker; Beta-Adrenergic Blocker; CCB=Calcium Channel Blocker; AAB=Alpha-Adrenergic Blocker; hsCRP=high-sensitivity C-Reactive Protein; Hb=Haemoglobin; 
Alb=Albumin; eGFR=estimated Glomerular Filtration Rate; ACR=Albumin : Creatinine Ratio; BMI=Body Mass Index; LTI= Lean Tissue Index; FTI=Fat Tissue Index; NODAT=New Onset 
Diabetes After Transplantation; Pre-DM=Presence of Diabetes Mellitus pre-transplantation. 
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 SDC, Table 1.  Predictors of Extracellular Volume Status (Percentage Volume 
Expansion, %VE) 
 Univariate Analysis Multivariate Analysis§ 
Regression 
Coefficient  
(95% CI∞) 
p-value Regression 
Coefficient  
(95% CI∞) 
p-value 
(***) Sodium intake (mg)  1.8 (1.3, 2.3) <0.001 1.7 (1.2, 2.4) <0.001 
(***) Fluid intake (mL)  1.4 (0.6, 2.0) <0.001   
(**) Age (years)  1.9 (0.9, 2.8) <0.001 1.8 (1.0, 2.6) <0.001 
Presence of diabetes 
Non-diabetic 
NODAT 
Pre-DM  
 
0 
2.4 (-1.2, 5.9) 
10.3 (6.0, 14.7) 
 
<0.001 
 
 
 
 
 
 
Gender 
Female 
Male 
 
0 
4.3 (1.6, 7.0) 
 
0.002 
  
Use of ACEI / ARB  
No 
Yes 
 
0 
3.6 (0.9, 6.3) 
 
0.01 
  
Number of antihypertensive medications 1.6 (0.1, 3.2) 0.04   
Alb (g/L) -0.4 (-0.8, 0.1) 0.11   
Use of diuretic (furosemide) 
No 
Yes 
 
0 
3.5 (-0.8, 7.8) 
 
0.11 
  
(*) FTI (kg/m2) -1.0 (-2.0, 0.5) 0.12 -1.4 (-2.2, -0.5) 0.002 
(*) eGFR (mL/min)  -0.3 (-0.6, 0.1) 0.19   
(ℓ) ACR (mg/mmol)  0.5 (-0.4, 1.4) 0.27   
‡Ethnicity 
Caucasian 
Non-Caucasian 
 
0 
-1.8 (-5.1, 1.5) 
 
0.29 
  
Use of prednisolone 
No 
Yes 
 
0 
-1.8 (-5.1, 1.6) 
 
0.29 
  
(*) LTI (kg/m2) -0.2 (-0.7, 0.2) 0.31   
†Smoking status 
Never smoked 
Ex-smoker / Current smoker 
 
0 
0.1 (-1.4, 4.3) 
 
0.32 
  
Use of BAB  
No 
Yes 
 
0 
0.2 (-1.3, 3.9) 
 
0.34 
  
Use of CCB 
No 
Yes 
 
0 
0.1 (-1.5, 4.1) 
 
0.34 
  
Hb (g/dL) -0.4 (-1.3, 0.5) 0.44   
Use of AAB 
No 
Yes 
 
0 
0.1 (-2.0, 3.9) 
 
0.52 
  
(*) Time post transplantation (years)  0.2 (-0.9, 1.3) 0.76   
Use of calcineurin inhibitor 
No 
Yes 
 
0 
-0.3, (-3.7, 3.1) 
 
0.85 
  
(ℓ) hsCRP (mg/L)  0.1 (-1.3, 1.4) 0.94   
Previous episodes of acute rejection 
No 
Yes 
 
0 
-0.1 (-3.4, 3.2) 
 
0.95 
  
Use of adjunctive antiproliferative agents 
No  
Yes 
 
0 
-0.0 (-4.6, 4.5) 
 
0.99 
  
R2 value from final model 51% 
§Results in the final multivariate regression model were presented.  
∞CI = Confidence Interval.   
†For the purpose of statistical analysis, smoking status was arranged into 2 categories, “non-smoker” versus “the combination of current smoker and ex-smoker”, 63% and 37% of patients 
respectively.   
‡For the purpose of statistical analysis, the ethnicity of patients classified as “Afro-Caribbean”, “Asian” and “Others” was grouped as “Non-Caucasian”, 77% “Caucasian” versus 23% “Non-
Caucasian”.   
(*) Coefficients reported for a 5-unit increase in explanatory variable.   
(**) Coefficients reported for a 10-unit increase in explanatory variable.  
(***) Coefficients reported for a 50-unit increase in explanatory variable.  
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 (ℓ) Variable analysed on the log scale (base 10). 
Abbreviations:  %VE=Percentage Volume Expansion; NODAT=New Onset Diabetes After Transplantation; Pre-DM=Presence of Diabetes Mellitus pre-transplantation; ACEI=Angiotensin-
Converting-Enzyme Inhibitor; ARB=Angiotensin-Receptor Blocker; Alb=Albumin; FTI=Fat Tissue Index; eGFR=estimated Glomerular Filtration Rate; ACR=Albumin : Creatinine Ratio; 
LTI= Lean Tissue Index; BAB=Beta-Adrenergic Blocker; CCB=Calcium Channel Blocker; Hb=Haemoglobin; AAB=Alpha-Adrenergic Blocker; hsCRP=high-sensitivity C-Reactive Protein. 
SDC, Table 2.  Predictors of Mean Arterial Pressure (MAP) 
 Univariate Analysis Multivariate Analysis§ 
Regression 
Coefficient  
(95% CI∞) 
p-value Regression 
Coefficient  
(95% CI∞) 
p-value 
(*) %VE 6.6 (5.6, 7.5) <0.001 6.6 (5.6, 7.6) <0.001 
(***) Sodium intake (mg)  0.3 (0.2, 0.4) <0.001   
(**) Age (years)  2.5 (0.9, 4.1) <0.01   
Presence of diabetes 
Non-diabetic 
NODAT 
Pre-DM  
 
0 
5.6 (2.1, 9.0) 
11.2 (2.8, 19.5) 
 
<0.01 
  
Use of ACEI / ARB  
No 
Yes 
 
0 
6.7 (2.1, 11.3) 
 
<0.01 
  
Alb (g/L) -0.9 (-1.7, -0.2) 0.01   
Gender 
Female 
Male 
 
0 
5.8 (1.1, 10.4) 
 
0.02 
  
(***) Fluid intake (mL)  0.2 (0.0, 0.3) 0.03   
Number of antihypertensive medications 2.7 (0.0, 5.4) 0.05   
‡Ethnicity 
Caucasian 
Non-Caucasian 
 
0 
5.0 (-0.5, 11.0) 
 
0.08 
  
(*) Time post transplantation (years)  1.2 (-0.6, 2.9) 0.18   
(*) FTI (kg/m2) 1.3 (-3.1, 0.6) 0.19   
Use of calcineurin inhibitor 
No 
Yes 
 
0 
3.6 (-2.2, 9.3) 
 
0.22 
  
Use of diuretic (furosemide) 
No 
Yes 
 
0 
4.0 (-2.5, 10.5) 
 
0.23 
  
Use of prednisolone 
No 
Yes 
 
0 
-2.5 (-8.1, 3.1) 
 
0.38 
  
Use of CCB 
No 
Yes 
 
0 
2.1 (-2.7, 6.8) 
 
0.39 
  
Use of BAB 
No 
Yes 
 
0 
3.2 (-2.9, 6.2) 
 
0.41 
  
(*) eGFR (mL/min)  -0.2 (-0.9, 0.5) 0.54   
Hb (g/dL) -0.5 (-2.0, 1.1) 0.56   
Use of adjunctive antiproliferative agents 
No  
Yes 
 
0 
2.2 (-5.3, 9.7) 
 
0.56 
  
Use of AAB 
No 
Yes 
 
0 
1.5 (-3.5, 6.5) 
 
0.56 
  
†Smoking status 
Never smoked 
Ex-smoker / Current smoker 
 
0 
1.4 (-3.5, 6.3) 
 
0.57 
  
LTI (kg/m2) -0.2 (-1.0, 0.6) 0.63   
(ℓ) hsCRP (mg/L)  1.1 (-3.8, 5.9) 0.66   
(ℓ) ACR (mg/mmol)  0.6 (-3.0, 4.3) 0.72   
Previous episodes of acute rejection 
No 
Yes 
 
0 
-0.5 (-6.1, 5.1) 
 
0.86 
  
R2 value from final model 62% 
§Results in the final multivariate regression model were presented.  
∞CI = Confidence Interval.   
†For the purpose of statistical analysis, smoking status was arranged into 2 categories, “non-smoker” versus “the combination of current smoker and ex-smoker”, 63% and 37% of patients 
respectively.   
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‡For the purpose of statistical analysis, the ethnicity of patients classified as “Afro-Caribbean”, “Asian” and “Others” was grouped as “Non-Caucasian”, 77% “Caucasian” versus 23% “Non-
Caucasian”.   
(*) Coefficients reported for a 5-unit increase in explanatory variable.   
(**) Coefficients reported for a 10-unit increase in explanatory variable.  
(***) Coefficients reported for a 50-unit increase in explanatory variable.  
 (ℓ) Variable analysed on the log scale (base 10). 
Abbreviations:  %VE=Percentage Volume Expansion; NODAT=New Onset Diabetes After Transplantation; Pre-DM=Presence of Diabetes Mellitus pre-transplantation; ACEI=Angiotensin-
Converting-Enzyme Inhibitor; ARB=Angiotensin-Receptor Blocker; Alb=Albumin; FTI=Fat Tissue Index; CCB=Calcium Channel Blocker; BAB=Beta-Adrenergic Blocker; eGFR=estimated 
Glomerular Filtration Rate; Hb=Haemoglobin; AAB=Alpha-Adrenergic Blocker; LTI= Lean Tissue Index; hsCRP=high-sensitivity C-Reactive Protein; ACR=Albumin : Creatinine Ratio. 
SDC, Table 3.  Predictors of Systolic Blood Pressure (SBP) 
 Univariate Analysis Multivariate Analysis§ 
Regression 
Coefficient  
(95% CI∞) 
p-value Regression 
Coefficient  
(95% CI∞) 
p-value 
(***) Sodium intake (mg)  0.4 (0.3, 0.6) <0.001   
(***) Fluid intake (mL)  0.2 (0.1, 0.4) <0.001   
(**) Age (years)  4.2 (2.0, 6.3) <0.001   
(*) %VE 9.7 (8.4, 11.0) <0.001 9.8 (8.5, 11.0) <0.001 
Presence of diabetes 
Non-diabetic 
NODAT 
Pre-DM  
 
0 
9.2 (4.3, 14.0) 
23.9 (12.7, 35.0) 
 
<0.001 
  
Use of ACEI / ARB  
No 
Yes 
 
0 
9.3 (2.8, 15.8) 
 
<0.01 
  
Gender 
Female 
Male 
 
0 
8.1 (1.5, 14.6) 
 
0.02 
  
Alb (g/L) -1.1 (-2.2, -0.1) 0.03   
Number of antihypertensive medications 3.3 (-0.5, 7.0) 0.09   
‡Ethnicity 
Caucasian 
Non-Caucasian 
 
0 
5.2 (2.7, 13.1) 
 
0.20 
  
(*) FTI (kg/m2) -1.6 (-4.2, 1.1) 0.24   
(ℓ) ACR (mg/mmol)  2.9 (-2.1, 8.0) 0.25   
Use of diuretic (furosemide) 
No 
Yes 
 
0 
-4.4 (-12.3, 3.5) 
 
0.28 
  
Use of prednisolone 
No 
Yes 
 
0 
-4.4 (-12.3, 3.5) 
 
0.28 
  
LTI (kg/m2) -0.6 (-1.8, 0.5) 0.28   
(*) Time post transplantation (years)  1.2 (-1.2, 3.7) 0.31   
Hb (g/dL) -0.9 (-3.1, 1.3) 0.42   
Use of calcineurin inhibitor 
No 
Yes 
 
0 
2.6 (-5.6, 10.7) 
 
0.53 
  
Use of BAB 
No 
Yes 
 
0 
-2.1 (-4.4, 7.2) 
 
0.55 
  
Previous episodes of acute rejection 
No 
Yes 
 
0 
-2.4 (-10.3, 5.6) 
 
0.56 
  
Use of CCB 
No 
Yes 
 
0 
1.7 (-5.0, 8.4) 
 
0.62 
  
†Smoking status 
Never smoked 
Ex-smoker / Current smoker 
 
0 
1.4 (-5.5, 8.3) 
 
0.69 
  
(*) eGFR (mL/min)  -0.2 (-1.2, 0.8) 0.71   
Use of AAB 
No 
Yes 
 
0 
1.2 (-5.9, 8.3) 
 
0.74 
  
(ℓ) hsCRP (mg/L)  0.9 (-6.0, 7.8) 0.80   
Use of adjunctive antiproliferative agents 
No  
Yes 
 
0 
0.4 (-10.2, 11.0) 
 
0.95 
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R2 value from final model 69% 
§Results in the final multivariate regression model were presented.  
∞CI = Confidence Interval.   
†For the purpose of statistical analysis, smoking status was arranged into 2 categories, “non-smoker” versus “the combination of current smoker and ex-smoker”, 63% and 37% of patients 
respectively.   
‡For the purpose of statistical analysis, the ethnicity of patients classified as “Afro-Caribbean”, “Asian” and “Others” was grouped as “Non-Caucasian”, 77% “Caucasian” versus 23% “Non-
Caucasian”.   
(*) Coefficients reported for a 5-unit increase in explanatory variable.   
(**) Coefficients reported for a 10-unit increase in explanatory variable.  
(***) Coefficients reported for a 50-unit increase in explanatory variable.  
 (ℓ) Variable analysed on the log scale (base 10). 
Abbreviations:  %VE=Percentage Volume Expansion; NODAT=New Onset Diabetes After Transplantation; Pre-DM=Presence of Diabetes Mellitus pre-transplantation; ACEI=Angiotensin-
Converting-Enzyme Inhibitor; ARB=Angiotensin-Receptor Blocker; Alb=Albumin; FTI=Fat Tissue Index; ACR=Albumin : Creatinine Ratio; LTI= Lean Tissue Index; Hb=Haemoglobin; 
BAB=Beta-Adrenergic Blocker; CCB=Calcium Channel Blocker; eGFR=estimated Glomerular Filtration Rate; AAB=Alpha-Adrenergic Blocker; hsCRP=high-sensitivity C-Reactive Protein. 
SDC, Table 4.  Predictors of Diastolic Blood Pressure (DBP) 
 Univariate Analysis Multivariate Analysis§ 
Regression 
Coefficient  
(95% CI∞) 
p-value Regression 
Coefficient  
(95% CI∞) 
p-value 
(*) %VE 5.0 (3.7, 6.2) <0.001 4.9 (3.7, 6.2) <0.001 
(***) Sodium intake (mg)  0.2 (0.1, 0.3) <0.01   
Use of ACEI / ARB  
No 
Yes 
 
0 
5.3 (0.7, 9.9) 
 
0.02 
  
Alb (g/L) -0.8 (-1.5, -0.1) 0.03   
(**) Age (years)  1.7 (0.1, 3.3) 0.04   
Presence of diabetes 
Non-diabetic 
NODAT 
Pre-DM  
 
0 
3.7 (0.2, 7.2) 
4.9 (-3.6, 13.4) 
 
0.04 
  
Gender 
Female 
Male 
 
0 
4.7 (0.0, 9.3) 
 
0.05 
  
‡Ethnicity 
Caucasian 
Non-Caucasian 
 
0 
4.9 (-0.6, 10.4) 
 
0.08 
  
Number of antihypertensive medications 2.4 (-0.3, 5.0) 0.08   
(***) Fluid intake (mL)  0.1 (-0.1, 0.2) 0.16   
Use of BAB 
No 
Yes 
 
0 
2.8 (-3.1, 4.8) 
 
0.16 
  
Use of calcineurin inhibitor 
No 
Yes 
 
0 
4.0 (-1.7, 9.6) 
 
0.16 
  
(*) Time post transplantation (years)  1.1 (-0.6, 5.6) 0.21   
†Smoking status 
Never smoked 
Ex-smoker / Current smoker 
 
0 
2.9 (-1.9, 7.7) 
 
0.23 
  
(*) FTI (kg/m2) -1.1 (-3.0, 0.7) 0.24   
Use of CCB 
No 
Yes 
 
0 
2.3 (-2.4, 7.0) 
 
0.34 
  
Use of adjunctive antiproliferative agents 
No  
Yes 
 
0 
3.2 (-4.1, 10.6) 
 
0.39 
  
(*) eGFR (mL/min)  -0.2 (-0.9, 0.5) 0.50   
Use of AAB 
No 
Yes 
 
0 
1.6 (-3.3, 6.5) 
 
0.53 
  
Use of diuretic (furosemide) 
No 
Yes 
 
0 
1.8 (-4.6, 8.2) 
 
0.58 
  
Use of prednisolone 
No 
Yes 
 
0 
-1.5 (-7.1, 4.0) 
 
0.59 
  
(ℓ) hsCRP (mg/L)  1.2 (-3.6, 6.0) 0.62   
(ℓ) ACR (mg/mmol)  -0.6 (-4.1, 3.0) 0.75   
Hb (g/dL) -0.2 (-1.7, 1.3) 0.77   
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Previous episodes of acute rejection 
No 
Yes 
 
0 
0.4 (-5.1, 6.0) 
 
0.87 
  
LTI (kg/m2) 0.0 (-0.8, 0.8) 0.91   
R2 value from final model 35% 
§Results in the final multivariate regression model were presented.  
∞CI = Confidence Interval.   
†For the purpose of statistical analysis, smoking status was arranged into 2 categories, “non-smoker” versus “the combination of current smoker and ex-smoker”, 63% and 37% of patients 
respectively.   
‡For the purpose of statistical analysis, the ethnicity of patients classified as “Afro-Caribbean”, “Asian” and “Others” was grouped as “Non-Caucasian”, 77% “Caucasian” versus 23% “Non-
Caucasian”.   
(*) Coefficients reported for a 5-unit increase in explanatory variable.   
(**) Coefficients reported for a 10-unit increase in explanatory variable.  
(***) Coefficients reported for a 50-unit increase in explanatory variable.  
 (ℓ) Variable analysed on the log scale (base 10). 
Abbreviations:  %VE=Percentage Volume Expansion; ACEI=Angiotensin-Converting-Enzyme Inhibitor; ARB=Angiotensin-Receptor Blocker; Alb=Albumin; NODAT=New Onset Diabetes 
After Transplantation; Pre-DM=Presence of Diabetes Mellitus pre-transplantation; BAB=Beta-Adrenergic Blocker; FTI=Fat Tissue Index; CCB=Calcium Channel Blocker; eGFR=estimated 
Glomerular Filtration Rate; AAB=Alpha-Adrenergic Blocker; hsCRP=high-sensitivity C-Reactive Protein; ACR=Albumin : Creatinine Ratio; Hb=Haemoglobin; LTI= Lean Tissue Index. 
SDC, Table 5.  Predictors of N-Terminal of prohormone B-type Natriuretic Peptide (NT-
proBNP) 
 Univariate Analysis Multivariate Analysis§ 
Ratio  
(95% CI∞) 
p-value Ratio 
(95% CI∞) 
p-value 
(*) %VE 1.38 (1.07, 1.78) 0.01 1.16 (1.03, 1.29) 0.01 
(*) eGFR (mL/min)  0.89 (0.80, 0.99) 0.03 0.95 (0.90, 0.99) 0.03 
Hb (g/dL) 0.74 (0.57, 0.96) 0.03 0.74 (0.58, 0.96) 0.02 
Use of CCB 
No 
Yes 
 
1 
0.84 (0.53, 1.05) 
 
0.09 
 
1 
0.63 (0.45, 0.89) 
 
<0.01 
(ℓ) ACR (mg/mmol)  1.24 (0.96, 1.60) 0.10   
Use of adjunctive antiproliferative agents 
No  
Yes 
 
1 
0.85 (0.40, 1.10) 
 
0.11 
  
†Smoking status 
Never smoked 
Ex-smoker / Current smoker 
 
1 
1.16 (0.93, 1.84) 
 
0.12 
 
1 
1.46 (1.04, 2.05) 
 
0.03 
LTI (kg/m2) 0.96 (0.91, 1.02) 0.20   
(**) Age (years)  1.20 (0.91, 1.59) 0.20   
(*) Time post transplantation (years)  1.20 (0.91, 1.60) 0.20   
‡Ethnicity 
Caucasian 
Non-Caucasian 
 
1 
0.56 (0.23, 1.40) 
 
0.21 
  
Use of prednisolone 
No 
Yes 
 
1 
0.17 (0.01, 4.75) 
 
0.29 
  
(ℓ) hsCRP (mg/L)  0.83 (0.58, 1.19) 0.31   
Gender 
Female 
Male 
 
1 
0.68 (0.32, 1.47) 
 
0.33 
  
Use of AAB 
No 
Yes 
 
1 
1.09 (0.82, 1.64) 
 
0.41 
  
Presence of diabetes 
Non-diabetic 
NODAT 
Pre-DM  
 
1 
2.02 (0.69, 5.96) 
1.32 (0.37, 4.70) 
 
0.42 
  
Use of BAB 
No 
Yes 
 
1 
0.98 (0.81, 1.28) 
 
0.45 
  
Use of calcineurin inhibitor 
No 
Yes 
 
1 
1.44 (0.52, 4.01) 
 
0.48 
  
(***) Fluid intake (mL)  1.07 (0.86, 1.33) 0.53   
Number of antihypertensive medications 0.95 (0.79, 1.16) 0.63   
Alb (g/L) 1.03 (0.91, 1.17) 0.67   
Use of diuretic (furosemide) 
No 
Yes 
 
1 
1.02 (0.67, 1.67) 
 
0.81 
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Use of ACEI / ARB  
No 
Yes 
 
1 
1.05 (0.48, 2.28) 
 
0.90 
  
(*) FTI (kg/m2) 1.01 (0.88, 1.15) 0.95   
(***) Sodium intake (mg)  1.01 (0.84, 1.20) 0.95   
Previous episodes of acute rejection 
No 
Yes 
 
1 
1.01 (0.36, 2.89) 
 
0.98 
  
R2 value from final model 21% 
§Results in the final multivariate regression model were presented.  
∞CI = Confidence Interval.   
†For the purpose of statistical analysis, smoking status was arranged into 2 categories, “non-smoker” versus “the combination of current smoker and ex-smoker”, 63% and 37% of patients 
respectively.   
‡For the purpose of statistical analysis, the ethnicity of patients classified as “Afro-Caribbean”, “Asian” and “Others” was grouped as “Non-Caucasian”, 77% “Caucasian” versus 23% “Non-
Caucasian”.   
(*) Coefficients reported for a 5-unit increase in explanatory variable.   
(**) Coefficients reported for a 10-unit increase in explanatory variable.  
(***) Coefficients reported for a 50-unit increase in explanatory variable.  
 (ℓ) Variable analysed on the log scale (base 10).  
Abbreviations:  NT-proBNP=N-Terminal pro B-type Natriuretic Peptide; %VE=Percentage Volume Expansion; eGFR=estimated Glomerular Filtration Rate; Hb=Haemoglobin; 
CCB=Calcium Channel Blocker; ACR=Albumin : Creatinine Ratio; LTI= Lean Tissue Index; hsCRP=high-sensitivity C-Reactive Protein; AAB=Alpha-Adrenergic Blocker; NODAT=New 
Onset Diabetes After Transplantation; Pre-DM=Presence of Diabetes Mellitus pre-transplantation; BAB=Beta-Adrenergic Blocker; Alb=Albumin; ACEI=Angiotensin-Converting-Enzyme 
Inhibitor; ARB=Angiotensin-Receptor Blocker; FTI=Fat Tissue Index. 
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